Day Trading Solutions

U-M researchers identify new blood test for prostate cancer

Stock Option Trading Test looks at 22 biomarkers; results more accurate than PSA

Currency Day Trading ANN ARBOR, Mich. - Researchers at the University of Michigan Comprehensive Cancer Center have identified a panel of 22 biomarkers that together provide a more accurate screening for prostate cancer than the current prostate specific antigen, or PSA, test.

A high level of lycopene in the blood serum correlates to a lower risk of prostate cancer, according to new research published in the latest edition of the American Journal of Epidemiology. Researchers from the US National Cancer Institute in Bethesda, Maryland, led by Dr Tara M. Vogt, focused on 437 men, some 209 of whom had prostate cancer. Vogt's team wanted to find conclusive evidence that the level of carotenoids such as lycopene found in the body were related to the incidence of prostate cancer, since earlier studies had given mixed results.

Financial Software Trading The study appears in the Sept. 22 issue of the New England Journal of Medicine.

The study of 345 women found that the test detected 95 percent of breast cancers, BBC News reported. The blood test developed by American and British researchers detects minor changes in the concentrations of certain proteins in the blood. Some of these proteins are specific for breast tissue, related inflammation and new blood vessel growth. The researchers said that by changing the combination of proteins the test detects, it could be used to spot other kinds of cancers, BBC News reported.

Online Stock Trading Company Researchers looked at blood samples taken from 331 prostate cancer patients prior to surgery, and from 159 control males with no history of cancer. They began by testing the samples against a library of 2,300 bacteriophage, organisms that express proteins on their surface, and were able to narrow the field to the 22 biomarkers that most often pinpointed the cancerous blood samples.

Because the evidence remains weak and mixed, shark cartilage remains unproven as a treatment for men with prostate cancer. Zinc Prostate cancer patients have been reported to have subnormal levels of zinc within the prostate, which might facilitate the growth of cancer, according to some researchers.⁹⁷ Zinc has interfered with the growth of prostate cancer cells in test tube research.⁹⁸ However, no trials have directly explored whether zinc supplements help prevent prostate cancer or can effectively treat men who already have the disease.

Forex Day Trading More than 230,000 men will be diagnosed with prostate cancer this year. Current screening methods involve a blood test to check for prostate specific antigen, an enzyme produced by the prostate. But the PSA test is controversial. A high level does not always indicate prostate cancer and some experts suggest a rise in PSA is more significant than a consistently high PSA. A high PSA level can also indicate benign prostate conditions.

Links have begun to appear between higher DHEA levels and risks of prostate cancer in humans.³⁵ At least one person with prostate cancer has been reported to have had a worsening of his cancer despite feeling better while taking very high amounts (up to 700 mg per day) of DHEA.³⁶ While younger women with breast cancer may have low levels of DHEA, postmenopausal women with breast cancer appear to have high levels of DHEA, which has researchers concerned.³⁷ These cancer concerns make sense because DHEA is a precursor to testosterone (linked to prostate cancer) and estrogen (linked to breast cancer).

Financial In Market "Initially, we envision this new test could be used as a supplement to PSA. A physician might suggest a patient with an elevated PSA have this test before a biopsy to better determine whether it's a cancerous or benign condition. In the future, I think this could replace PSA," says lead study author Arul Chinnaiyan, M.D., Ph.D., the S.P. Hicks Collegiate Professor of Pathology at the U-M Medical School.

Stock Trading System In the current study, researchers first tested the blood serum samples of 39 men with prostate cancer and 21 controls to identify autoantibodies against prostate cancer. Cancer patients produce antibodies that fight against proteins that play a role in cancer. The researchers scanned 2,300 autoantibodies and initially narrowed it down to 186 that reacted with blood serum from the men with prostate cancer.

Day Trading Stock Tip This discovery phase formed the basis for the next round of tests, in which 59 prostate cancer samples and 70 control samples were tested against the 186 autoantibodies. In this phase, the researcher identified a panel of 22 compounds that best distinguished the prostate cancer blood samples from the controls. Using these 22 markers, only two of 70 controls incorrectly tested positive for prostate cancer, and seven of 59 prostate cancer samples were falsely negative.

Financial Forex Forex Software Next, the researchers validated their findings using the remaining 128 blood serum samples. They found eight of 68 controls and 11 of 60 prostate cancer samples were misclassified. This means 88 percent of the time, samples that were not cancerous were correctly identified and 81.6 percent of the time, samples that were cancerous tested positive.

Stock Market Trading "These 22 biomarkers appear to be the right number. If you used too many or too few, the accuracy went down a bit. Our findings held up when we tested the model on an independent set of blood serum samples," Chinnaiyan says.

Day Lesson Stock Tip Trading The results proved to be more reliable at predicting cancer than prostate specific antigen, which is a single biomarker. PSA testing results in a false positive around 80 percent of the time, leading to unnecessary prostate biopsies. The normal range for the PSA test is less than 4.0 nanograms per milliliter (ng/mL) in most men. For men over 40 years old with a family history of prostate disease or for African-American men over 40 years old, some doctors suggest that a level higher than 2.5 ng/mL should be checked with more tests, because these two groups of men have an increased risk of prostate cancer.

Financial System Trading The 22-biomarker test was reliable at identifying prostate cancer even in the PSA ranges of 4-10 ng/ml or 2.5-10 ng/ml, intermediate PSA scores that do not always suggest cancer. The study authors suggest the 22 biomarkers could be used for patients in this range to help determine whether to undergo a biopsy.

Day Trading Future The new test requires only a routine blood draw for patients. Most blood-processing laboratories could easily be equipped to scan for these 22 biomarkers, Chinnaiyan says. Researchers are conducting further studies to validate the findings with a larger, community-based group of patients.

Financial Forex Market Trading University of Michigan Health System

[ Comment, Edit or Article Submission ]